Table 5.

Univariable and multivariable regression models evaluating risk factors for severe Covid-19.

	Univariable Analysis n=309		Multivariable Analysis n=309		Stepwise Multivariate Analysis n = 309
Variable	OR (95% C.I.)	p	OR (95% C.I.)	p	OR (95% C.I.)	OR (95% C.I.)
Age	1.03 (1.01 – 1.06)	0.016	1.02 (0.99 – 1.05)	0.21
Sex (Male vs Female)	1.30 (0.77 – 2.18)	0.33	1.41 (0.80 – 2.47)	0.23
Smoking (Current/former vs Never)	0.99 (0.59 – 1.67)	0.97	0.94 (0.54 – 1.65)	0.83
MS type (Progressive vs RR)	2.93 (1.39 – 6.15)	0.005	1.97 (0.73 – 5.35)	0.18	2.36 (1.09 - 5.13)	0.029
EDSS	1.40 (1.21 – 1.62)	<0.001	/
Disease duration (years)	1.01 (0.97 – 1.06)	0.57	/
MSSS (≥ 7 vs <7)	2.57 (1.33 – 4.97)	0.005	2.17 (1.07 – 4.40)	0.031	2.13 (1.07 - 4.23)	0.032
BMI	0.99 (0.94 – 1.04)	0.58	0.99 (0.94 – 1.05)	0.74
Presence of comorbidities	1.53 (0.74 – 3.19)	0.26	1.32 (0.58 -2.99)	0.50
Methylprednisolone with in 1 month prior to Covid-19 onset	1.28 (0.59 – 2.78)	0.53	1.26 (0.56 – 2.84)	0.58
Disease modifying therapy
Fingolimod / Natalizumab	Ref.		Ref.
Interferon / Glatiramer acetate	0.57 (0.29 – 1.12)	0.11	0.64 (0.32 - 1.27)	0.20
Teriflunomide / Dymethil fumarate	0.73 (0.37 – 1.45)	0.37	0.76 (0.38 - 1.52)	0.44
Ocrelizumab/Rituximab	1.17 (0.54 – 2.53)	0.69	0.64 (0.26 - 1.60)	0.34
None	1.06 (0.42 – 2.70)	0.90	0.77 (0.28 - 2.11)	0.61

OUTCOME = ICU/death vs Only hospitalized vs Others